DBV Technologies announces its financial results and clinical progress for the first half of 2026

DBV Technologies, specializing in the treatment of food allergies, has published its results for the first half of 2026. The company reports cash reserves of $174.9 million, sufficient to fund its operations until the third quarter of 2027. Its operating revenue for this period reached $1.6 million, down compared to 2025.

DBV has intensified its efforts in developing the VIASKIN® Peanut patch, anticipating a license application submission to the FDA in Q3 2026. Additional clinical studies are ongoing for children and toddlers with peanut allergies. In parallel, the company is strengthening its preparations for the planned commercial launch.

R&D expenses increased to $64.6 million, reflecting intensified research. Commercial expenses totaled $36.3 million to support expansion in the United States. Despite a net loss of $98 million, the company continues to invest in these key areas.